Search

Your search keyword '"Déchenaud, Marie"' showing total 4 results
Start Over Author "Déchenaud, Marie"
4 results on '"Déchenaud, Marie"'

1. CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death

Author

Lévy, Yves, Wiedemann, Aurélie, Hejblum, Boris P., Durand, Mélany, Lefebvre, Cécile, Surénaud, Mathieu, Lacabaratz, Christine, Perreau, Matthieu, Foucat, Emile, Déchenaud, Marie, Tisserand, Pascaline, Blengio, Fabiola, Hivert, Benjamin, Gauthier, Marine, Cervantes-Gonzalez, Minerva, Bachelet, Delphine, Laouénan, Cédric, Bouadma, Lila, Timsit, Jean-François, Yazdanpanah, Yazdan, Pantaleo, Giuseppe, Hocini, Hakim, and Thiébaut, Rodolphe

Published
2021
Full Text
View/download PDF

3. CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death

Author

Lévy, Yves, primary, Wiedemann, Aurélie, additional, Hejblum, Boris P., additional, Durand, Mélany, additional, Lefebvre, Cécile, additional, Surénaud, Mathieu, additional, Lacabaratz, Christine, additional, Perreau, Matthieu, additional, Foucat, Emile, additional, Déchenaud, Marie, additional, Tisserand, Pascaline, additional, Blengio, Fabiola, additional, Hivert, Benjamin, additional, Gauthier, Marine, additional, Cervantes-Gonzalez, Minerva, additional, Bachelet, Delphine, additional, Laouénan, Cédric, additional, Bouadma, Lila, additional, Timsit, Jean-François, additional, Yazdanpanah, Yazdan, additional, Pantaleo, Giuseppe, additional, Hocini, Hakim, additional, and Thiébaut, Rodolphe, additional

Published
2023
Full Text
View/download PDF

4. Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients

Author

Wiedemann, Aurélie, Pellaton, Céline, Dekeyser, Manon, Guillaumat, Lydia, Déchenaud, Marie, Krief, Corinne, Lacabaratz, Christine, Grimbert, Philippe, Pantaleo, Giuseppe, Lévy, Yves, Durrbach, Antoine, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), IMRB - 'From pathophysiology towards immune-basedinterventions in HIV infection' [Créteil] (U955 Inserm - UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Vaccine Research Institute [Créteil, France] (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Lausanne = University of Lausanne (UNIL), Institut Gustave Roussy (IGR), Immunologie intégrative des tumeurs et immunothérapie des cancers (INTIM), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Henri Mondor, Service de néphrologie et transplantation, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Lausanne University Hospital, AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses 94000 Créteil, France, Department of Nephrology [Le Kremlin-Bicêtre], Institut francilien de recherche en néphrologie et transplantation [Le Kremlin-Bicêtre] (IFRNT), Université Paris-Sud - Paris 11 (UP11)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris-Sud - Paris 11 (UP11)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), and European Project: CoVICIS

Subjects
immunosuppressive regimen, immunocompromised, mRNA vaccine, [SDV]Life Sciences [q-bio], COVID-19, General Medicine, immune responses
Abstract

International audience; Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regimens on cellular and humoral responses to SARS-CoV-2 variants of concern in this context. We performed a prospective longitudinal study assessing specific humoral (binding and neutralizing antibodies against spike (S) and T-lymphocyte (cytokine secretion and polyfunctionality) immune responses to anti-COVID-19 vaccination with at least two doses of BNT162b2 mRNA vaccine in stable kidney transplant recipients (KTR) on calcineurin inhibitor (CNI)- or belatacept-based treatment regimens. Fifty-two KTR−31 receiving CNI and 21 receiving belatacept—were enrolled in this study. After two doses of vaccine, 46.9% of patients developed anti-S IgG. Anti-spike IgG antibodies were produced in only 21.4% of the patients in the belatacept group, vs. 83.3% of those in the CNI group. The Beta and Delta variants and, more importantly, the Omicron variant, were less well neutralized than the Wuhan strain. T-cell functions were also much weaker in the belatacept group than in the CNI group. Renal transplant patients have an impaired humoral response to BNT162b2 vaccination. Belatacept-based regimens severely weaken both humoral and cellular vaccine responses. Clinically, careful evaluations of at least binding IgG responses, and prophylactic or post-exposure strategies are strongly recommended for transplant recipients on belatacept-based regimens.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results